MedTrace Logo

Chlorzoxazone in Hip and Knee Arthroplasty

NCT02405104 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2019-09-09

No results posted yet for this study

Summary

The purpose of this study is to elucidate whether patients operated with THA and TKA can benefit from treatment with chlorzoxazone.

Conditions

  • Osteoarthritis of Hip
  • Osteoarthritis, Knee

Interventions

DRUG

chlorzoxazone

ATC-code: M03BB03

DRUG

Placebo

Placebo

PROCEDURE

THA

Surgical treatment of osteoarthrosis in the hip, by replacement.

PROCEDURE

TKA

Surgical treatment of osteoarthrosis in the knee, by replacement.

Sponsors & Collaborators

  • Northern Orthopaedic Division, Denmark

    lead OTHER

Principal Investigators

  • Mogens Laursen, MD, PhD · Northern Orthopaedic Division, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2017-12-31
Completion
2019-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02405104 on ClinicalTrials.gov